Haleon

Haleon plc
	Headquarters in Weybridge, UK
Company type	Public limited company
Traded as	LSE: HLN; NYSE: HLN; FTSE 100 component;
ISIN	GB00BMX86B70
Industry	Healthcare; Consumer goods;
Predecessors	GSK Consumer Healthcare; Pfizer Consumer Healthcare (second incarnation); Wyeth Consumer Healthcare; Novartis Consumer Healthcare;
Founded	18 July 2022
Headquarters	Weybridge, England, United Kingdom
Area served	Worldwide
Key people	Sir Dave Lewis (chairman); Brian McNamara (CEO);
Products	Oral hygiene and medicines; nutritional products; over-the-counter medicines;
Brands	Actifed; Advil; Aquafresh; Beechams; Biotene; Caltrate; Centrum; Contac; Emergen-C; Eno; Excedrin; Fenbid; Fenistil; Flonase; Foodles; Loviscol; Maclean; Nexium; Nicorette; Nicotinell; Odol; Otrivin; Panadol; Parodontax; Polident; Sensodyne; Theraflu; Tums; Voltaren;
Revenue	£11,030 million (2025)
Operating income	£2,412 million (2025)
Net income	£1,680 million (2025)
Total assets	£32,630 million (2025)
Total equity	£16,484 million (2025)
Number of employees	24,000 (2024)
Subsidiaries	Haleon Pakistan
Website	www.haleon.com

Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins. The company was projected to be a global leader in over the counter medicines with a 7.3 per cent market share in 2022.

Haleon was established on 18 July 2022 as a corporate spin-off from GSK. Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange.